Trial Profile
A Phase I Single-Dose Study of RO7046015 in Healthy Japanese Men
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Prasinezumab (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical; Prothena; Roche
- 27 Aug 2018 Status changed from active, no longer recruiting to completed.
- 18 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Feb 2018 Status changed from not yet recruiting to recruiting.